Shots:
- Sprint Bioscience has reported the sale of its TREX1 cancer program to Gilead Sciences
- As per the Deal, Sprint Bioscience will receive $14M upfront and up to $400M in clinical, regulatory, and commercial milestones
- TREX1 program has demonstrated notable potential in the pre-clinical stage
Ref: Sprint Bioscience | Image: Gilead & Sprint Bioscience | Press Release
Related News: Gilead Highlights P-III (ASCENT-03) Trial Data of Trodelvy for Triple-Negative Breast Cancer (TNBC) at ESMO 2025
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
